caa a22 4500 469073896 CHVBK 20180323132929.0 cr unu---uuuuu 170328e19920701xx s 000 0 eng 10.1007/BF01789328 doi (NATIONALLICENCE)springer-10.1007/BF01789328 Detection of allogeneic Qa/TL and Ly specificities on murine tumor cells with IgD in tumor-regressor serum [Elektronische Daten] [Takae Tanino, Naohiro Seo, Takahiro Okazaki, Chiemi Nakanishi-Ito, Masayuki Sekimata, Kohji Egawa] Summary: Serum from C3H/He mice, which show regression of MM2 tumor cells after transplantation and removal (regressor serum, RS) contains non-gammaglobulin components that cross-react with various tumor cells of mice [22, 23]. In addition to tumor cells, various allogeneic lymphocytes are also susceptible to an RS-dependent lymphocyte-mediated cytotoxic reaction. To identify tumor cell surface antigens that cause the cross-reactive host response, the serum components were analyzed by absorption of RS with allogeneic lymphocytes. RS components were found to recognize allogeneic lymphocyte antigens including Qa-2 and Ly6.2. Specificity for the Qa-2 antigen was further tested using Qa-2-congenic mice. The expression of Qa-2 antigen was detected on the surfaces of MM2 and other tumor cells derived from H-2k mice (seven among nine cell lines tested) by a membrane immunofluorescence method using a Qa-2-specific mAb. Physical characteristics of the Qa-2-specific component in RS were determined and found to differ from those of regular IgGs but to be similar to those of IgDs. Using an enzyme-linked immunosorbent assay with an IgD-specific mAb and Qa-2-lacZ fusion protein, the existence of IgD in RS with specificity for Qa-2 was confirmed. These results suggest that the RS component with Qa-2 specificity is an IgD, the specificity and physiological role of which are unknown. Springer-Verlag, 1992 Tumor antigen nationallicence Qa-2 nationallicence IgD nationallicence Tanino Takae Department of Tumor Biology, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, 108, Minatoku, Tokyo, Japan aut Seo Naohiro Department of Tumor Biology, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, 108, Minatoku, Tokyo, Japan aut Okazaki Takahiro Department of Tumor Biology, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, 108, Minatoku, Tokyo, Japan aut Nakanishi-Ito Chiemi Department of Tumor Biology, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, 108, Minatoku, Tokyo, Japan aut Sekimata Masayuki Department of Tumor Biology, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, 108, Minatoku, Tokyo, Japan aut Egawa Kohji Department of Tumor Biology, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, 108, Minatoku, Tokyo, Japan aut Cancer Immunology, Immunotherapy Springer-Verlag 35/4(1992-07-01), 230-236 0340-7004 35:4<230 1992 35 262 https://doi.org/10.1007/BF01789328 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01789328 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Tanino Takae Department of Tumor Biology, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, 108, Minatoku, Tokyo, Japan aut NATIONALLICENCE 700 1- Seo Naohiro Department of Tumor Biology, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, 108, Minatoku, Tokyo, Japan aut NATIONALLICENCE 700 1- Okazaki Takahiro Department of Tumor Biology, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, 108, Minatoku, Tokyo, Japan aut NATIONALLICENCE 700 1- Nakanishi-Ito Chiemi Department of Tumor Biology, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, 108, Minatoku, Tokyo, Japan aut NATIONALLICENCE 700 1- Sekimata Masayuki Department of Tumor Biology, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, 108, Minatoku, Tokyo, Japan aut NATIONALLICENCE 700 1- Egawa Kohji Department of Tumor Biology, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, 108, Minatoku, Tokyo, Japan aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 35/4(1992-07-01), 230-236 0340-7004 35:4<230 1992 35 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer